英文名稱：(Urine CartiLaps® ELISA)
生產(chǎn)廠商：艾狄斯
【預(yù)期用途】
本產(chǎn)品僅供科研使用。尿中II型膠原C端肽酶聯(lián)免疫吸附分析試劑盒(UrineCartiLaps® ELISA)檢測人尿中II型膠原C端肽(CTX一II)降解產(chǎn)物。
IDS公司對將試劑用于除上面指定用途以外的任何其他用途的后果不予負(fù)責(zé)，對未按照本手冊所示方法而錯(cuò)誤使用本試劑不予負(fù)責(zé)；此外，對由使用者或第三方根據(jù)尿中II型膠原C端肽酶聯(lián)免疫吸附分析試劑盒的結(jié)果所做診斷或結(jié)論，以及其解釋所導(dǎo)致的任何后果不予負(fù)責(zé)。
【背景介紹】
軟骨結(jié)構(gòu)完整性的損傷是骨關(guān)節(jié)炎和類風(fēng)濕關(guān)節(jié)炎的主要組織學(xué)表現(xiàn)。II型膠原蛋白是軟骨的主要有機(jī)成分。軟骨降解后，II型膠原蛋白的片段(CTX-II)釋放進(jìn)入循環(huán)系統(tǒng)，隨后 排入尿中。尿中的CTX-II片段可由尿中II型膠原C端肽酶聯(lián)免疫吸附分析試劑盒定量檢測。
據(jù)報(bào)道，尿中II型膠原C端肽酶聯(lián)免疫吸附分析有利于預(yù)測骨關(guān)節(jié)炎的發(fā)展(Reijman 2003, Garnero 2003) 及其它臨床和臨床前研究(見參考文獻(xiàn))。
【樣本要求】
建議取第二次晨尿樣本，也可使用任何時(shí)間點(diǎn)的尿樣。尿樣在4°C下24小時(shí)內(nèi)穩(wěn)定，長期儲(chǔ)存應(yīng)冷凍存放（<-18°C）。尿 樣至少在10 次凍融周期內(nèi)保持穩(wěn)定。使用前尿樣應(yīng)震蕩并沉淀至少30分鐘。
【參考文獻(xiàn)】
- Ceunick F De, Sabatini
M, Renoux V, Nanteuil G de, Pastoureau P. Urinary collagen type II
C-telopeptide fragments are sensitive markers of matrix metallo-proteinase
dependent cartilage degradation in rat adjuvant induced arthritis. J
Rheumatol (2003); 30: 1561-1564.
- Christgau S, Tankó LB,
Cloos PAC, Mouritzen U, Christiansen C, Delaissé J-M, Høegh-Andersen P.
Suppression of Elevated Cartilage Turnover in Postmenopausal Women and in
Ovariectomized Rats by Estrogen and a Selective Estrogen Receptor
Modulator (SERM). Submitted.
- Christgau S, Henrotin Y,
Henriksen DB, Rovati LC, Collette J, Bruyere O, Deroisy R, Christiansen C,
Reginster JY. Cartilage Degradation In Glucosamine Sulphate Treated Knee
Osteoarthritis Patients With Elevated Levels Of Urinary Collagen Type II
Ctelopeptide Fragments. Clin Exp Rheumatol. 2004 Jan-Feb;22(1):36-42
- Christgau S, Garnero P,
Fledelius C, Moniz C, Rosenquist C, Ensig M, Gineyts E, Christiansen C,
Qvist P. Collagen type II degradation products in urine as an index of
cartilage degradation. Bone (2001); 29: 209-215.
- Forsblad d’Elia H, Christgau
S, Mattsson L-Å, Saxne T, Ohlsson C, Nordborg E, Carlsten H. Hormone
replacement therapy decreases markers of cartilage and bone metabolism in
rheumatoid arthritis. Submitted.
- Garnero P, Mazières B,
Gueguen A, Abbal M, Berdah L, Freiburghaus C, Lequesne M, Nguyen M,
Salles J-P, Vignon E, Dougados M. Association of 10 molecular markers of
bone, cartilage and synovium with disease activity and joint damage in hip
osteoarthritis patients: the ECHODIAH cohort. ACR 2003.
- Garnero P, Landewé R,
Boers M, Verhoeven A, Linden S van der, Christgau S, Heijde D van der,
Boonen A, Geusens P. Association of baseline levels of markers of bone and
cartilage degradation with long-term progression of joint damage in
patients with early rheumatoid arthritis: the COBRA Study. Arthritis &
Rheum (2002); 46:2847-2856.
- Garnero P, Ayral X,
Rousseau J-C, Christgau S, Sandell L, Delmas PD, Dougados M. Uncoupling of
type II collagen synthesis and degradation predicts progression of joint
damage in patients with knee osteoarthritis. Arthritis & Rheum (2002);
46:2613-2624.
- Garnero P, Gineyts E,
Christgau S, Finck B, Delmas PD. Association of baseline levels of urinary
glucosyl-galactosyl pyridinoline and type II collagen C-telopeptide with
progression of joint destruction in patients with early rheumatoid
arthritis. Arthritis & Rheum (2002); 46: 21-30.
- Garnero P, Christgau S,
Delmas PD. The bisphosphonate Zoledronate decreases type II collagen
breakdown in patients with Paget’s disease of bone. Bone (2001); 28:
461-464.
- Garnero P, Piperno M,
Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of
biochemical markers of bone, cartilage, and synovial tissue metabolism in
patients with knee osteoarthritis: relations with disease activity and
joint damage. Ann Rheum Dis. (2001); 60: 619-26.
- Høegh-Andersen P, Tankó
LB, Andersen T, Vingsbo C, Heegaard A-M, Delaissé J-M, Christgau S.
Ovariectomized Rats as a Model of Postmenopausal Osteoarthritis.
Validation and Application. Annals of Rheum Dis. (2004); 6(2): R169-80
- Jensen T, Hansen M,
Stoltenberg M, Christgau S, Florescu A, Sommarin Y, Lorenzen I.
Biochemical markers of connective tissue metabolism in patients with
rheumatoid arthritis. Relationship to disease activity, radiographic
outcome and bone mineral density. Submitted.
- Jung M, Christgau S,
Lukoschek M, Henriksen DB, Richter W. Elevated urinary concentration of
collagen type II C-telopeptide fragments in patients with osteoarthritis.
Pathobiology. (2004); 71(2): 70-6
- Lehmann HJ, Mouritzen U,
Christgau S, Cloos PAC, Christiansen C. The effects of bisphosphonates on
CartiLaps: A new marker for cartilage degradation. Annals of Rheumatic
Diseases (2002); 61:530-533.
- Mazières B, Garnero P,
Gueguen A, Abbal M, Berdah L, Freiburghaus C, Lequesne M, Nguyen M, Salles
J-P, Vignon E, Dougados M. Molecular markers of cartilage breakdown and
synovitis are strong independent predictors of structural progression of
hip osteoarthritis (OA). the ECHODIAH cohort. ACR 2003.
- Mouritzen U, Christgau
S, Lehmann HJ, Tankó LB, Christiansen C. CartiLaps: A novel marker of
Cartilage Degradation. The influence of age, gender, menopause, hormone
replacement therapy and bone mass index. Annals Rheum Dis. (2003); 62:
332-336.
- Roy-Beaudry M,
Martel-Pelletier J, Pelletier J-P, M’Barek KN, Christgau S, Shipkolye F,
Moldovan F. Entothelin-1 promotes osteoarthritic cartilage degradation via
mmp-1 and mmp-13 induction. Arthritis & Rheum (2003); 48:2855-2864.
